It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.

Durham-based Tavros Therapeutics, a precision oncology company spun out of Duke University, has been acquired by a subsidiary of global life sciences titan Bayer AG. Financial terms of the deal with ...

(Tune Photos) Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.